Sana Biotechnology, Inc. License Agreements
38 Contracts & Agreements
- Second Amendment to Exclusive License Agreement by and between the Company and The Regents of the University of California acting through the Technology Development Group of The... (Filed With SEC on August 8, 2024)
- Amendment No. 4 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of April 4, 2024 (Filed With SEC on May 8, 2024)
- Amendment No. 1 to Amended and Restated Exclusive Patent License Agreement by and between the Company and Rochester, dated as of December 30, 2022 (Filed With SEC on February 29, 2024)
- First Amendment to Exclusive License Agreement by and between the Company and The Regents acting through The Technology Development Group of UCLA, dated as of May 21, 2021 (Filed With SEC on February 29, 2024)
- Amendment No. 3 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of March 17, 2023 (Filed With SEC on May 8, 2023)
- Amendment No. 2 to Non-Exclusive License and Development Agreement by and between the Company and FCDI, dated as of October 26, 2021 (Filed With SEC on March 16, 2023)
- Amendment No. 1 to Non-Exclusive License and Development Agreement by and between the Company and FCDI, dated as of April 12, 2021 (Filed With SEC on March 16, 2023)
- Fifth Amendment to License Agreement by and between the Company and Harvard, dated as of February 9, 2023 (Filed With SEC on March 16, 2023)
- Amendment No. 11 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of July 14, 2022 (Filed With SEC on November 2, 2022)
- Amendment No. 10 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of October 30, 2021 (Filed With SEC on November 2, 2022)
- Amendment No. 9 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of September 9, 2021 (Filed With SEC on November 2, 2022)
- Amendment No. 8 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of July 20, 2021 (Filed With SEC on November 2, 2022)
- Amendment No. 7 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of April 14, 2021 (Filed With SEC on November 2, 2022)
- Amendment No. 6 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of March 11, 2021 (Filed With SEC on November 2, 2022)
- Amendment No. 5 to Exclusive Start-Up License Agreement by and between the Company and University of Washington (UW), dated as of February 25, 2021 (Filed With SEC on November 2, 2022)
- Amendment No. 2 to Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of July 19, 2022 (Filed With SEC on November 2, 2022)
- Amendment No. 1 to Option and License Agreement, by and between the Company and Beam Therapeutics Inc., dated as of June 6, 2022 (Filed With SEC on August 4, 2022)
- Patent License Agreement by and between the Company and the U.S. Department of Health and Human Services, as represented by The National Cancer Institution, an institute of the... (Filed With SEC on March 16, 2022)
- Fourth Amendment to License Agreement by and between the Company and Harvard, dated as of October 25, 2021 (Filed With SEC on March 16, 2022)
- Third Amendment to License Agreement by and between the Company and Harvard, dated as of May 20, 2021 (Filed With SEC on March 16, 2022)
- Option and License Agreement, effective October 15, 2021, by and between the Company and Beam Therapeutics Inc (Filed With SEC on November 8, 2021)
- Non-Exclusive License and Development Agreement by and between the Registrant and Fujifilm Cellular Dynamics, Inc., effective on February 1, 2021 (Filed With SEC on February 2, 2021)
- Amendment No. 4 to Exclusive Start-Up License Agreement, effective on January 21, 2021 by and between the Registrant and UW (Filed With SEC on January 28, 2021)
- Amendment No. 2 to Exclusive Start-Up License Agreement, effective on July 16, 2020, by and between Cytocardia and UW (Filed With SEC on January 28, 2021)
- Assignment of Exclusive Start-Up License Agreement, effective on November 11, 2020, by and among UW, Cytocardia and the Registrant (Filed With SEC on January 13, 2021)
- Amendment No. 1 to Exclusive Start-Up License Agreement, effective on November 6, 2019, by and between Cytocardia and UW (Filed With SEC on January 13, 2021)
- Exclusive Start-Up License Agreement, effective on October 9, 2018, by and between Cytocardia, Inc. (Cytocardia) and the University of Washington, acting through UW CoMotion (UW) (Filed With SEC on January 13, 2021)
- Amended and Restated Exclusive Patent License Agreement, dated September 10, 2020, by and among the Registrant, Oscine Corp., and University of Rochester (Filed With SEC on January 13, 2021)
- Exclusive License Agreement, effective on September 1, 2020, by and between the Registrant and Washington University (Filed With SEC on January 13, 2021)
- Exclusive License Agreement, effective on November 14, 2019, by and between the Registrant and Washington University (Filed With SEC on January 13, 2021)
- Amendment No. 1 to Exclusive License Agreement, effective on December 3, 2020, by and between the Registrant and UCSF (Filed With SEC on January 13, 2021)
- Exclusive License Agreement, effective on January 2, 2019, by and between the Registrant and The Regents, acting through its Office of Technology Management, University of... (Filed With SEC on January 13, 2021)
- Amendment No. 2 to License Agreement, dated as of December 15, 2020, by and between the Registrant and Harvard (Filed With SEC on January 13, 2021)
- Amendment No. 1 to License Agreement, dated as of June 10, 2019, by and between the Registrant and Harvard (Filed With SEC on January 13, 2021)
- License Agreement, dated as of March 19, 2019, by and between the Registrant and President and Fellows of Harvard College (Harvard) (Filed With SEC on January 13, 2021)
- Exclusive License Agreement, dated March 22, 2019, by and between the Registrant and the Regents of the University of California (The Regents) acting through the Technology... (Filed With SEC on January 13, 2021)
- First Amendment to License Agreement, dated as of February 14, 2019, by and between Flagship Innovations V and Cobalt (Filed With SEC on January 13, 2021)
- License Agreement, effective as of February 17, 2016, by and between Flagship Pioneering Innovations V, Inc. (Flagship Innovations V) and Cobalt Biomedicine, Inc. (Cobalt) (Filed With SEC on January 13, 2021)
